Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation.

ABSTRACT:

Background

The development of accurate urinary biomarkers for non-invasive and cost-effective detection of primary and recurrent bladder tumours is recognized as one of the major clinical needs in bladder cancer diagnostics. The purposes of this study were (1) to validate the results of a previous technical comparison by determining the diagnostic performance of nine methylation markers in urine pellet compared to full void urine, and (2) to validate the diagnostic performance of the optimal marker panel GHSR/MAL from a previous exploratory study in a preclinical setting.

Methods

Urine samples of 108 patients with bladder cancer and 100 age- and gender-matched controls were prospectively collected for methylation analysis. Urinary methylation levels of the markers FAM19A4, G

SUBMITTER: Hentschel AE 

PROVIDER: S-EPMC8818199 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature